C. S. Bland, “The Halsted mastectomy: present illness and past history.,” West. J. Med., vol. 134, no. 6, pp. 549–55, Jun. 1981.
 W. J. Gradishar et al., “NCCN Guidelines Insights: Breast Cancer, Version 1.2017.,” J. Natl. Compr. Canc. Netw., vol. 15, no. 4, pp. 433–451, 2017.
 M. B. Amin et al., “The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging,” CA. Cancer J. Clin., vol. 67, no. 2, pp. 93–99, Mar. 2017.
 M. Kalager, M. Zelen, F. Langmark, and H.-O. Adami, “Effect of Screening Mammography on Breast-Cancer Mortality in Norway,” N. Engl. J. Med., vol. 363, no. 13, pp. 1203–1210, Sep. 2010.
 S. Saadatmand, R. Bretveld, S. Siesling, and M. M. A. Tilanus-Linthorst, “Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients.,” BMJ, vol. 351, p. h4901, Oct. 2015.
 Independent UK Panel on Breast Cancer Screening, “The benefits and harms of breast cancer screening: an independent review,” Lancet, vol. 380, no. 9855, pp. 1778–1786, Nov. 2012.
 Y. Gocgun et al., “Cost-effectiveness of breast cancer screening policies using simulation,” The Breast, vol. 24, no. 4, pp. 440–448, Aug. 2015.
 M. G. Marmot et al., “The benefits and harms of breast cancer screening: an independent review.,” Br. J. Cancer, vol. 108, no. 11, pp. 2205–40, Jun. 2013.
 M. Ghoncheh, Z. Pournamdar, and H. Salehiniya, “Incidence and Mortality and Epidemiology of Breast Cancer in the World.,” Asian Pac. J. Cancer Prev., vol. 17, no. S3, pp. 43–6, 2016.
 M. Ridao-López, S. García-Armesto, B. Abadía-Taira, S. Peiró-Moreno, and E. Bernal-Delgado, “Income level and regional policies, underlying factors associated with unwarranted variations in conservative breast cancer surgery in Spain,” BMC Cancer, vol. 11, no. 1, p. 145, Dec. 2011.
 M. Pera, “Variabilidad en la práctica quirúrgica. Un problema por resolver,” Cirugía Española, vol. 95, no. 2, pp. 59–61, Feb. 2017.
 E. Rococo, C. Mazouni, Z. Or, V. Mobillion, M. Koon Sun Pat, and J. Bonastre, “Variation in rates of breast cancer surgery: A national analysis based on French Hospital Episode Statistics,” Eur. J. Surg. Oncol., vol. 42, no. 1, pp. 51–58, Jan. 2016.
 L. Blay et al., “Variabilidad en la práctica de la cirugía mamaria en mujeres participantes en el programa de cribado poblacional de cáncer de mama,” Cirugía Española, vol. 97, no. 2, pp. 89–96, Feb. 2019.
 M. A. Gilligan, R. T. Kneusel, R. G. Hoffmann, A. L. Greer, and A. B. Nattinger, “Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption.,” Med. Care, vol. 40, no. 3, pp. 181–9, Mar. 2002.
 E. Angulo-Pueyo, M. Ridao-López, N. Martínez-Lizaga, S. García-Armesto, and E. Bernal-Delgado, “Variabilidad y coste de oportunidad de las alternativas quirúrgicas en cáncer de mama,” Gac. Sanit., vol. 28, no. 3, pp. 209–214, May 2014.
 D. L. Wickerham, S. A. Anderson, B. Fisher, R. Margolese, T. Mamounas, and N. Wolmark, “NSABP Protocol B-06: A randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer — Results after 15 years of follow-up,” Eur. J. Cancer, vol. 34, p. S38, Sep. 1998.
 U. Veronesi et al., “Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer,” N. Engl. J. Med., vol. 347, no. 16, pp. 1227–1232, Oct. 2002.
 J. Landercasper, E. Whitacre, A. C. Degnim, and M. Al-Hamadani, “Reasons for Re-Excision After Lumpectomy for Breast Cancer: Insight from the American Society of Breast Surgeons MasterySM Database,” Ann. Surg. Oncol., vol. 21, no. 10, pp. 3185–3191, Oct. 2014.
 F. Gani, D. J. Lucas, Y. Kim, E. B. Schneider, and T. M. Pawlik, “Understanding variation in 30-day surgical readmission in the era of accountable care: Effect of the patient, surgeon, and surgical subspecialties,” JAMA Surg., vol. 150, no. 11, pp. 1042–1049, Nov. 2015.
 I. Chow, P. J. Hanwright, N. M. Hansen, S. N. Leilabadi, and J. Y. S. Kim, “Predictors of 30-day readmission after mastectomy: A multi-institutional analysis of 21,271 patients,” Breast Dis., vol. 35, no. 4, pp. 221–231, Nov. 2015.
 J. Landercasper, B. Bennie, M. S. Bray, C. A. Vang, and J. H. Linebarger, “Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer?,” Gland Surg., vol. 6, no. 1, pp. 14–26, 2017.
 S. Gibson and R. McConigley, “Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study,” Support. Care Cancer, vol. 24, no. 1, pp. 311–317, Jan. 2016.
 P. Glasziou and N. Houssami, “The evidence base for breast cancer screening,” Prev. Med. (Baltim)., vol. 53, no. 3, pp. 100–102, Sep. 2011.
 “CaMISS – Cáncer de mama. Investigación en servicios sanitarios.” [Online]. Available: https://www.camiss.info/. [Accessed: 17-Jul-2019].
 N. Perry, M. Broeders, C. de Wolf, S. Tornberg, R. Holland, and L. von Karsa, “European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document,” Ann. Oncol., vol. 19, no. 4, pp. 614–622, Oct. 2007.
 N. Ascunce et al., “Cancer screening in Spain,” Ann. Oncol., vol. 21, no. Supplement 3, pp. iii43–iii51, May 2010.
 G. H. Lyman et al., “American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer,” J. Clin. Oncol., vol. 23, no. 30, pp. 7703–7720, Oct. 2005.
 A. Romero et al., “Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs,” BMC Cancer, vol. 16, no. 1, p. 735, Dec. 2016.
 E. Hashemi, A. Kaviani, M. Najafi, M. Ebrahimi, H. Hooshmand, and A. Montazeri, “Seroma formation after surgery for breast cancer,” World J. Surg. Oncol., vol. 2, no. 1, p. 44, Dec. 2004.
 A. J. M. van Bemmel, C. J. H. van de Velde, R. F. Schmitz, and G. J. Liefers, “Prevention of seroma formation after axillary dissection in breast cancer: A systematic review,” Eur. J. Surg. Oncol., vol. 37, no. 10, pp. 829–835, Oct. 2011.
 E. C. Coveney, P. J. O’Dwyer, J. G. Geraghty, and N. J. O’Higgins, “Effect of closing dead space on seroma formation after mastectomy--a prospective randomized clinical trial.,” Eur. J. Surg. Oncol., vol. 19, no. 2, pp. 143–6, Apr. 1993.
 S. Y. Boostrom et al., “Incidence of Clinically Significant Seroma after Breast and Axillary Surgery,” J. Am. Coll. Surg., vol. 208, no. 1, pp. 148–150, Jan. 2009.
 A. F. Vitug and L. A. Newman, “Complications in Breast Surgery,” Surg. Clin. North Am., vol. 87, no. 2, pp. 431–451, Apr. 2007.
 M. Ashraf, J. Biswas, S. Gupta, and N. Alam, “Determinants of wound infections for breast procedures: Assessment of the risk of wound infection posed by an invasive procedure for subsequent operation,” Int. J. Surg., vol. 7, no. 6, pp. 543–546, 2009.
 P. Volkow, D. Vilar-Compte, B. Jacquemin, and C. Robles-Vidal, “Surgical Site Infections in Breast Surgery: Case-control Study,” World J. Surg., vol. 28, no. 3, pp. 242–246, Mar. 2004.
 C.-L. Tran, S. Langer, G. Broderick-Villa, and L. A. DiFronzo, “Does reoperation predispose to postoperative wound infection in women undergoing operation for breast cancer?,” Am. Surg., vol. 69, no. 10, pp. 852–6, Oct. 2003.
 A. E. Giuliano et al., “Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: Long-term follow-up from the American college of surgeons oncology group (Alliance) ACOSOG Z0011 randomized trial,” Ann. Surg., vol. 264, no. 3, pp. 413–419, Sep. 2016.
 C. Miret et al., “Factors associated with readmissions in women participating in screening programs and treated for breast cancer: A retrospective cohort study,” BMC Health Serv. Res., vol. 19, no. 1, p. 940, Dec. 2019.
 S. R. Greysen, I. S. Cenzer, A. D. Auerbach, and K. E. Covinsky, “Functional impairment and hospital readmission in medicare seniors,” JAMA Intern. Med., vol. 175, no. 4, pp. 559–565, Apr. 2015.
 J. Billings, J. Dixon, T. Mijanovich, and D. Wennberg, “Case finding for patients at risk of readmission to hospital: Development of algorithm to identify high risk patients,” Br. Med. J., vol. 333, no. 7563, pp. 327–330, Aug. 2006.
 D. Kansagara et al., “Risk prediction models for hospital readmission: A systematic review,” JAMA - Journal of the American Medical Association, vol. 306, no. 15. pp. 1688–1698, 19-Oct-2011.
 L. Mayhew, “On the effectiveness of care co-ordination services aimed at preventing hospital admissions and emergency attendances,” Health Care Manag. Sci., vol. 12, no. 3, pp. 269–284, Jul. 2009.
 M. Colleoni et al., “Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V,” J. Clin. Oncol., vol. 34, no. 9, pp. 927–935, Mar. 2016.
 A. M. Brewster et al., “Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy,” JNCI J. Natl. Cancer Inst., vol. 100, no. 16, pp. 1179–1183, Aug. 2008.
 G. van Tienhoven et al., “Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.,” Eur. J. Cancer, vol. 35, no. 1, pp. 32–8, Jan. 1999.
 E. C. Behm et al., “Surgical margins and risk of locoregional recurrence in invasive breast cancer: An analysis of 10-year data from the Breast Cancer Treatment Quality Assurance Project,” The Breast, vol. 22, no. 5, pp. 839–844, Oct. 2013.
 J. A. Hattangadi-Gluth et al., “Basal Subtype of Invasive Breast Cancer Is Associated With a Higher Risk of True Recurrence After Conventional Breast-Conserving Therapy,” Int. J. Radiat. Oncol., vol. 82, no. 3, pp. 1185–1191, Mar. 2012.
 A. J. Lowery, M. R. Kell, R. W. Glynn, M. J. Kerin, and K. J. Sweeney, “Locoregional recurrence after breast cancer surgery: A systematic review by receptor phenotype,” Breast Cancer Research and Treatment, vol. 133, no. 3. pp. 831–841, Jun-2012.
 I. Jatoi and M. A. Proschan, “Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results.,” Am. J. Clin. Oncol., vol. 28, no. 3, pp. 289–94, Jun. 2005.
 J. A. van Dongen et al., “Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial,” J. Natl. Cancer Inst., vol. 92, no. 14, pp. 1143–1150, Jul. 2000.
 G. H. de Bock, J. A. van der Hage, H. Putter, J. Bonnema, H. Bartelink, and C. J. van de Velde, “Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer studies,” Eur. J. Cancer, vol. 42, no. 3, pp. 351–356, Feb. 2006.
 P. M. P. Poortmans, M. Arenas, and L. Livi, “Over-irradiation,” The Breast, vol. 31, pp. 295–302, Feb. 2017.
 N. Johns and J. M. Dixon, “Should patients with early breast cancer still be offered the choice of breast conserving surgery or mastectomy?,” Eur. J. Surg. Oncol., vol. 42, no. 11, pp. 1636–1641, Nov. 2016.
 R. Arriagada, M. G. Lê, F. Rochard, and G. Contesso, “Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group.,” J. Clin. Oncol., vol. 14, no. 5, pp. 1558–1564, May 1996.
 H. B. Neuman et al., “Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01),” J. Clin. Oncol., vol. 36, no. 10, pp. 975–980, Apr. 2018.
 S. Lanitis, P. P. Tekkis, G. Sgourakis, N. Dimopoulos, R. Al Mufti, and D. J. Hadjiminas, “Comparison of Skin-Sparing Mastectomy Versus Non–Skin-Sparing Mastectomy for Breast Cancer,” Ann. Surg., vol. 251, no. 4, pp. 632–639, Apr. 2010.
 H. Medina-Franco et al., “Factors Associated With Local Recurrence After Skin-Sparing Mastectomy and Immediate Breast Reconstruction for Invasive Breast Cancer,” Ann. Surg., vol. 235, no. 6, pp. 814–819, Jun. 2002.
 S. Agarwal, L. Pappas, L. Neumayer, K. Kokeny, and J. Agarwal, “Effect of Breast Conservation Therapy vs Mastectomy on Disease-Specific Survival for Early-Stage Breast Cancer,” JAMA Surg., vol. 149, no. 3, p. 267, Mar. 2014.
 O. J. Hartmann-Johnsen, R. Kåresen, E. Schlichting, and J. F. Nygård, “Better survival after breast-conserving therapy compared to mastectomy when axillary node status is positive in early-stage breast cancer: a registry-based follow-up study of 6387 Norwegian women participating in screening, primarily operated between 1998 and 2009.,” World J. Surg. Oncol., vol. 15, no. 1, p. 118, Jul. 2017.
 E. S. Hwang, D. Y. Lichtensztajn, S. L. Gomez, B. Fowble, and C. A. Clarke, “Survival after lumpectomy and mastectomy for early stage invasive breast cancer,” Cancer, vol. 119, no. 7, pp. 1402–1411, Apr. 2013.
 K. Chen, J. Liu, L. Zhu, F. Su, E. Song, and L. K. Jacobs, “Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: A NCDB analysis,” Oncotarget, vol. 6, no. 37, pp. 40127–40, Nov. 2015.
 M. Lagendijk et al., “Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients,” Int. J. Cancer, vol. 142, no. 1, pp. 165–175, Jan. 2018.
 A. M. Mazor et al., “Breast conservation versus mastectomy in patients with T3 breast cancers (> 5 cm): an analysis of 37,268 patients from the National Cancer Database,” Breast Cancer Res. Treat., vol. 173, no. 2, pp. 301–311, Jan. 2019.
 R. J. Bleicher et al., “Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients,” Cancer, vol. 122, no. 1, pp. 42–49, Jan. 2016.
 S. Hofvind, Å. Holen, T. Aas, M. Roman, S. Sebuødegård, and L. A. Akslen, “Women treated with breast conserving surgery do better than those with mastectomy independent of detection mode, prognostic and predictive tumor characteristics,” Eur. J. Surg. Oncol., vol. 41, no. 10, pp. 1417–1422, Oct. 2015.
 Y. Chen, L. Jiang, B. Gao, Z. Cheng, J. Jin, and K. Yang, “Survival and disease-free benefits with mastectomy versus breast conservation therapy for early breast cancer: a meta-analysis,” Breast Cancer Res. Treat., vol. 157, no. 3, pp. 517–525, Jun. 2016.
 C. A. Parise and V. Caggiano, “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors,” Breast Cancer Res. Treat., vol. 165, no. 3, pp. 743–750, Oct. 2017.
 M. J. Piccart-Gebhart et al., “Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer,” N. Engl. J. Med., vol. 353, no. 16, pp. 1659–1672, Oct. 2005.
 A. Schramm, N. De Gregorio, P. Widschwendter, V. Fink, and J. Huober, “Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review,” Breast Care, vol. 10, no. 3, pp. 173–178, Jul. 2015.